Market Overview

OHK Medical Devices & Mitsubishi Corp. to Launch HemaClear® in Japan

Share:

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile, exsanguinating tourniquet device, announced today that it has entered an exclusive agreement with Japan Medicalnext Co.,Ltd., a Mitsubishi Corporation company, to introduce HemaClear® to the Japanese market.

Haifa, Israel (PRWEB) June 13, 2013

OHK Medical Devices Ltd., manufacturer of the HemaClear® single-use, sterile exsanguinating tourniquet device, announced today that it has entered an exclusive agreement with Japan Medicalnext Co., Ltd, a Mitsubishi Corporation company, for the distribution of HemaClear® in Japan. OHK and Japan Medicalnext Co, will formally launch their entry into the Japanese market over the coming months. The Japanese orthopedic devices market, estimated at $1.4billion and growing at an annual rate of about 5%, represents one the largest markets in the world

“We are very excited to enter one of the largest global markets with such a well respected partner,” said Omer Inbar, CEO, OHK Medical Devices. Inbar added that “The introduction of HemaClear® in Japan is an important step in further establishing HemaClear® as a standard of care in the APAC market following our recent launch of HemaClear® in South Korea, Australia, and Thailand

“We are very excited to launch this new tourniquet technology in the Japanese market,” said Takeru Fujihashi, Vice President of Orthopedic Division, Japan Medicalnext Co., Ltd. “The technology will lead a major change in the current procedure and will create new benefits to the market.” Hemaclear® will be represented by the orthopedic implant division of Japan Medicalnext co., which includes 50 sales representative selling both external and internal fixation technologies.

About HemaClear®

HemaClear® is the world's leading sterile tourniquet with a simple yet innovative technology, representing a new standard of care in bloodless orthopedic surgery. Since entering the market in 2007 this product has been successfully used in more than 500,000 procedures. HemaClear® represents the first significant advancement in tourniquet technology in over 100 years. HemaClear® was developed by OHK Medical Devices (OHK), a privately held company based in Haifa, Israel and the United States and is currently used in over 2000 operating rooms across 30 countries. For more information about HemaClear®, visit http://www.hemaclear.com.

About Japan Medicalnext Co., Ltd.

Company was originally established in 1992, and was taken over by Mitsubishi Corporation in 2012. Then, Company changed company name as “Japan Medicalnext Co., Ltd.”, and made a new start. Company's mission is to optimize quality of life for patients by providing new technology and new medical devices. http://www.j-mednext.co.jp.

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2013/6/prweb10821754.htm

View Comments and Join the Discussion!